Kyle Jenne has rejoined Ionis Pharmaceuticals Inc. as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company.
 
Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another opportunity. To support the transition, Cadoret-Manier will remain in a full-time capacity through March 15, after which she will serve as an advisor for a period of time.
 
“I thank Onaiza for her tremendous vision and contributions in establishing Ionis’ foundational commercial organization and capabilities over the last four years as Ionis evolved into a fully integrated biopharmaceutical company. She has built a stellar team of professionals with deep experience across all aspects of commercialization,” said Brett P. Monia, Ionis’ chief executive officer. “With these core capabilities in place and our first co-commercialization underway for WAINUA (eplontersen), we’re excited to welcome Kyle back to spearhead our commercial growth as we work to advance a steady cadence of medicines starting with our first potential independent U.S. launches for olezarsen in familial chylomicronemia syndrome and donidalorsen in hereditary angioedema. Kyle’s broad commercial and launch experience, coupled with his strong existing relationships at Ionis, will enable him to rapidly and seamlessly add value to our commercial organization during this important time for Ionis and the patients who are counting on us.”

About Kyle Jenne

Jenne has more than 25 years of biopharmaceutical commercial and executive leadership experience and has launched innovative medicines across a broad range of therapeutic areas including cardiovascular, neurology and allergy.
 
Jenne previously spent five years in commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020. His most recent role at Ionis was as EVP & chief commercial officer. During his time at Ionis and Akcea, Jenne built commercial capabilities in many of Ionis’ key disease areas including transthyretin-mediated amyloidosis and familial chylomicronemia syndrome (FCS). He also played a key role in establishing the co-commercialization collaboration with AstraZeneca for WAINUA.
 
Earlier in his career, Jenne held commercial roles for companies including Schering Plough, King Pharmaceuticals, Acorda Therapeutics and Praecis Pharmaceuticals.
 
“As a fully integrated biopharma company, Ionis is demonstrating its leadership with an innovative pipeline of wholly owned mid- and late-stage investigational medicines, each of which has the potential to meet important unmet needs for people with serious diseases. I am committed to ensuring we fully realize the potential of these innovative medicines to reach patients and their healthcare providers, beginning with the anticipated upcoming launches for olezarsen and donidalorsen,” said Jenne. “On a personal level, I’m thrilled to be back at Ionis working with this incredibly talented and dedicated team.”